SCHEMBL3537302

SCHEMBL3537302

COC(=O)C(O)Cc1ccccc1Cl

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
NPC1 O15118 3/20 0.49
HTT P42858 2/20 0.48
RAB9A P51151 3/20 0.46
PPARG P37231 1/20 0.46
PPARA Q07869 1/20 0.46
KMT2A Q03164 2/20 0.44
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 1/20 0.43
EPHX2 P34913 1/20 0.41
GAA P10253 1/20 0.41
NOS3 P29474 1/20 0.41
NOS1 P29475 1/20 0.41
NOS2 P35228 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9767979 0.85 ALDH1A1 (0.52) ALDH1A1NPC1HTTRAB9APPARG
SCHEMBL28364980 0.84 ALDH1A1 (0.49) ALDH1A1NPC1HTTRAB9APPARG
SCHEMBL18801970 0.84 ALDH1A1 (0.49) ALDH1A1NPC1HTTRAB9APPARG
SCHEMBL16808693 0.84 ALDH1A1 (0.49) ALDH1A1NPC1HTTRAB9APPARG
SCHEMBL16808562 0.84 ALDH1A1 (0.49) ALDH1A1NPC1HTTRAB9APPARG
SCHEMBL2153012 0.82 ALDH1A1 (0.50) ALDH1A1NPC1HTTRAB9APPARG
SCHEMBL1066220 0.82 ALDH1A1 (0.50) ALDH1A1NPC1HTTRAB9APPARG
SCHEMBL4595262 0.82 ALDH1A1 (0.50) ALDH1A1NPC1HTTRAB9APPARG
SCHEMBL11444938 0.82 ALDH1A1 (0.50) ALDH1A1NPC1HTTRAB9APPARG
SCHEMBL14119246 0.81 LTA4H (0.52) ALDH1A1NPC1HTTRAB9APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642277-B2 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-05 US disclosed
EP-1569919-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2005-09-07 EP disclosed
US-20050054639-A1 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-03-10 US disclosed
WO-2004050643-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-06-17 WO disclosed
EP-0816316-A1 PROCESS FOR PRODUCING 1,2-ETHANEDIOL DERIVATIVES NITTO CHEMICAL INDUSTRY CO., LTD. (JP) 1998-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054639-A1 Non-nucleoside reverse transcriptase inhibitors NAT1, SUB1, RTF2 ALDH1A1 1533/4885NPC1 2263/4885HTT 2004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.